Incyte Announces Executive Leadership Appointments As part of the transition, Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period. For more background on Incyte's Leadership Team, please visit https://incyte.com/our-company/our- leadership. Mar 25, 2026 9:00 AM Eastern Daylight Time Incyte Announces Executive Leadership Appointments Share WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (NASDAQ:INCY) today announced appointments among its e ...

Core Viewpoint - Incyte (INCY) is identified as a strong investment opportunity within the healthcare sector, particularly for investors seeking undervalued companies [1] Group 1: Company Overview - Incyte is a global biopharmaceutical company focused on discovering, developing, and selling proprietary therapeutics [1] Group 2: Investment Strategy - The investment strategy emphasizes identifying small cap companies with strong fundamentals and growth potential, large cap companies experiencing temporary setbacks, and stable companies with solid dividend yields and growth potential [1]

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting Mar 20, 2026 10:00 AM Eastern Daylight Time Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting Share - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nas ...

Core Viewpoint - The investment debate surrounding Incyte (INCY) focuses on the potential loss of exclusivity for Jakafi in the US by 2028, which may overshadow the company's strong pipeline and growth in other existing products [1] Group 1: Company Analysis - Incyte's future performance may be underestimated due to the consensus estimates that do not fully account for its robust pipeline [1] - The company has existing products that are expected to contribute to growth, indicating potential resilience despite the loss of exclusivity for Jakafi [1] Group 2: Analyst Background - The analysis is conducted by a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management, emphasizing a focus on equity valuation and market trends [1] - The analyst has a background as a former Vice President at Barclays, leading teams in model validation and stress testing, which adds credibility to the insights provided [1]

MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., have submitted a supplemental application to ANMAT, the Argentinian health regulatory agency, and COFEPRIS, the Mexican health regulatory agency, respectively, seeking approval for an additional indication for MINJUVI® ...

Core Viewpoint - The article emphasizes the importance of investing in high-quality growth and momentum stocks that are reasonably priced, with a focus on long-term performance and potential market outperformance [1]. Group 1: Investment Strategy - The investment strategy involves focusing on growth and momentum stocks that are expected to outperform the market over the long term [1]. - The analyst has a history of advising investors to buy at market lows, specifically mentioning a recommendation in March 2009 during the financial crisis, which led to significant market gains [1]. Group 2: Market Performance - From 2009 to 2019, the S&P 500 increased by 367%, while the Nasdaq saw an increase of 685%, highlighting the potential for substantial returns in the stock market [1]. Group 3: Investment Philosophy - The analyst aims to assist investors in making money by investing in high-quality growth stocks, indicating a commitment to long-term investment strategies [1].

Upgrades - Keefe Bruyette upgraded Rocket Companies (RKT) to Outperform from Market Perform with a price target of $22, up from $20, citing valuation as shares are down 25% year-to-date [2] - Keefe Bruyette upgraded PennyMac Financial (PFSI) to Outperform from Market Perform with an unchanged price target of $115, indicating a 38% upside to the price target based on valuation [2] - Berenberg upgraded Ecolab (ECL) to Buy from Hold with a price target of $326, up from $300, expecting swift implementation of price increases to become a "sticky component" of Ecolab's pricing strategy [3] - Arete upgraded Trade Desk (TTD) to Neutral from Sell with a price target of $25, noting pressure on management to restore investor confidence as shares are down 49% in the last 12 months [3] - Clear Street upgraded Circle Internet (CRCL) to Buy from Hold with a price target of $136, up from $92, citing five catalysts for USDC market cap and adoption despite a 44% drawdown in broader crypto markets [4] Downgrades - Seaport Research downgraded Qualcomm (QCOM) to Sell from Neutral with a price target of $100, predicting that the memory crunch will adversely affect Qualcomm's customers and market share [5] - Argus downgraded Adobe (ADBE) to Hold from Buy, despite a 12% growth in operating income in Q1, due to overshadowing concerns from the announcement of CEO Narayan's resignation [5] - Jefferies downgraded Incyte (INCY) to Hold from Buy with a price target of $94, down from $120, citing patent cliff concerns [5] - Jefferies downgraded Alnylam (ALNY) to Hold from Buy with a price target of $330, down from $522, stating that shares are "priced to perfection" despite being impressed with the company's RNAi platform [5] - Jefferies downgraded Immunocore (IMCR) to Hold from Buy with a price target of $33, down from $48, noting that while Kimmtrak is a real product, the total addressable market is moderate and sales are nearing peak [5]

Regulatory Approvals - The European Commission approved Johnson & Johnson's AKEEGA for metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations, marking its second approval in the EU [2] - Protalix BioTherapeutics received approval for a new dosing regimen of Elfabrio, allowing for 2 mg/kg every four weeks for adults with Fabry disease [5] - Incyte's Zynyz received a second indication for the first-line treatment of advanced squamous cell carcinoma of the anal canal [10] Clinical Trial Results - AKEEGA demonstrated a clinically meaningful delay in disease progression in the phase 3 AMPLITUDE trial, nearly halving the risk of progression or death compared to standard care [3] Product Details - AKEEGA was initially approved in April 2023 for metastatic castration-resistant prostate cancer (mCRPC) and is also approved in the U.S. for BRCA2-mutated metastatic castration-sensitive prostate cancer [4] - Elfabrio was originally approved in May 2023 with a dosing regimen of 1 mg/kg every two weeks [7] - Zynyz generated net product revenue of $66 million in 2025, a significant increase from $3.19 million in 2024 [12]

Core Business Overview - The company estimates that its core business, excluding Jakafi, has the potential to reach sales of approximately $3 billion to $4 billion over the next 5 years [2] - The core business includes FDA-approved marketed products such as Opzelura, Niktimvo, and Monjuvi, which are expected to grow to a size comparable to Jakafi by 2030 [2] - Additional products in the pipeline, including XR and povorcitinib, are anticipated to receive approval within the next 12 months [2] Research and Development Focus - The company has a pipeline of 7 assets, with about 80% of its R&D investment concentrated in the areas of hematology, oncology, and immunology [3]

Incyte 2026 Conference Summary Company Overview - Incyte is focusing on three main dimensions: core business excluding Jakafi, pipeline development, and business development strategies. The core business is projected to reach $3-$4 billion in sales over the next five years, with products like Opzelura, Niktimvo, and Monjuvi contributing significantly by 2030 [4][5]. Core Product - Jakafi - Jakafi has shown a year-over-year growth of approximately 10% in 2025. The company aims to maintain a mid-single-digit growth rate until the end of 2028, with the launch of Jakafi XR expected to preserve revenue post-exclusivity loss [7][12]. - The company anticipates converting 15%-30% of Jakafi users to Jakafi XR, potentially preserving around $750 million in revenue during the transition [8]. Pipeline Development - Incyte has a pipeline of seven assets, with 80% of R&D investment focused on hematology, oncology, and immunology. There are 14 clinical studies planned for 2026 [4][5]. - The pipeline has the potential to generate 2-3 times the current top-line sales, indicating significant growth opportunities [5]. INCA33989 and CALR Pathway - INCA33989 is a monoclonal antibody targeting CALR mutations, showing promising results in early studies for myelofibrosis (MF) and essential thrombocythemia (ET). The drug aims to improve clinical endpoints such as spleen volume reduction and symptom improvement [21][25]. - The drug has demonstrated a superior profile compared to Jakafi, with potential for disease modification by eradicating cells with driver mutations [26][27]. - Phase 3 studies for INCA33989 are set to begin in mid-2026, with the potential to change treatment paradigms for MPNs [21][22]. Competitive Landscape - The company believes that no current or upcoming treatments will disrupt Jakafi's standard of care in the near future, positioning Jakafi as a stable revenue source [18]. - INCA33989 is expected to reshape treatment for patients intolerant to hydroxyurea, which is currently the standard of care for ET [42][47]. Upcoming Products - Povoricitinib is expected to launch in Q1 2027, with potential for significant sales across multiple indications, including hidradenitis suppurativa (HS) and vitiligo. The drug is positioned as a first-line treatment option due to its oral administration and rapid efficacy [55][56]. - The company anticipates capturing a substantial market share in HS, where treatment options are currently limited [56][59]. Conclusion - Incyte is strategically positioned for growth with a robust pipeline and established products. The focus on molecular-targeted therapies, particularly INCA33989, could redefine treatment standards in hematology, while Jakafi remains a critical revenue driver during the transition to new products [4][5][21].